Psychiatric Medications and Protein Binding

Introduction to Psychiatric Medications

• The American Academy of Child and Adolescent Psychiatry recommends monitoring for signs of valproic acid toxicity closely, as free drug concentrations may be elevated despite normal total concentrations, in patients with hypoalbuminemia 4
• The American Academy of Child and Adolescent Psychiatry suggests checking baseline and periodic liver function tests, complete blood counts, and albumin levels every 3-6 months in patients on valproic acid 4
• The Journal of Hepatology and other sources indicate that medications like phenytoin, phenobarbital, and carbamazepine are enzyme inducers that affect drug metabolism but do not reduce protein or albumin levels 1, 2, 5

Drug Interactions and Monitoring

• The American Heart Association, as published in Circulation: Arrhythmia and Electrophysiology, notes that carbamazepine can increase valproate clearance and may necessitate a 50% increase in warfarin maintenance dose 1, 2
• The American Thoracic Society, as published in Chest, recommends considering dose reduction if free concentrations are elevated or toxicity symptoms appear in patients on valproic acid 2

Patient Management

• The American Academy of Child and Adolescent Psychiatry recommends obtaining free valproic acid levels rather than total levels to accurately assess drug exposure in patients with suspected or confirmed hypoalbuminemia 4
• The Neuro-Oncology journal suggests watching for thrombocytopenia and hepatotoxicity, particularly in patients with additional risk factors 4, 7